EVis Bioscience Recognized Among Europe’s Top Cell and Gene Therapy Companies

EVis Bioscience has been featured by Life Sciences Review Europe ➚ among the Top Companies in Cell and Gene Therapy in Europe, a recognition reserved for organizations driving meaningful innovation in the life sciences sector.

The selection highlights EVis Bioscience’s work in RNA delivery and targeted gene therapy, acknowledging the company’s technological approach and its potential impact on the development of next-generation therapies.

Industry Acknowledgement

Life Sciences Review Europe identifies a limited number of companies each year based on editorial evaluation and industry nominations, focusing on scientific innovation, technological differentiation, and relevance within the European biotech landscape.

EVis Bioscience was recognized for its hybrid RNA delivery platform, which integrates stabilized extracellular vesicles with engineering-driven control to enable efficient RNA loading, targeted delivery, and scalability—addressing key challenges of current gene therapy technologies.

Award for Targeted Gene Therapy Development

In addition to being listed among the top cell and gene therapy companies➚, EVis Bioscience received the “Top Targeted Gene Therapy Medicines Development Company in Europe 2026” award.
This distinction further underlines the company’s focus on precision, biological alignment, and translational applicability in RNA-based therapeutic development.

Continuing the Path Forward

This recognition represents an important milestone as EVis Bioscience continues to advance its platform and expand its presence within the European gene therapy ecosystem.

👉 Read the full feature on Life Sciences Review Europe➚